Association between serum gastric biomarkers and metabolic syndrome.
10.11817/j.issn.1672-7347.2025.240324
- Author:
Wen ZENG
1
,
2
;
Shanhu YAO
3
;
Ying LI
1
;
Jiangang WANG
1
;
Yuexiang QIN
1
,
4
Author Information
1. Health Management Medical Center, Third Xiangya Hospital, Central South University, Changsha
2. 253773118@qq.com.
3. Department of Radiology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
4. 602466@csu.edu.cn.
- Publication Type:Journal Article
- Keywords:
gastric biomarkers;
gastrin-17;
metabolic syndrome;
pepsinogen;
sex difference
- MeSH:
Humans;
Metabolic Syndrome/epidemiology*;
Female;
Male;
Middle Aged;
Adult;
Cross-Sectional Studies;
Biomarkers/blood*;
Aged;
Young Adult;
Adolescent;
Gastrins/blood*;
Pepsinogen A/blood*;
Pepsinogen C/blood*;
Aged, 80 and over
- From:
Journal of Central South University(Medical Sciences)
2025;50(4):641-650
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:Metabolic syndrome (MetS) is a major public health concern that poses a significant threat to human health. Investigating its underlying mechanisms and identifying potential intervention targets has important clinical implications. This study aims to explore the association between serum gastric biomarkers and MetS and its components.
METHODS:A cross-sectional study was conducted among 24 635 individuals (aged 18 to 80 years) who underwent routine health examinations from May 2017 to June 2021 at the Health Management Medical Center, Third Xiangya Hospital, Central South University. Demographic data, medical and medication history, height, weight, blood pressure, fasting blood glucose, glycated hemoglobin (HbA1c), total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and creatinine levels were collected. Serum levels of pepsinogen (PG) I, PGII, and gastrin-17 (G-17) were measured using enzyme-linked immunosorbent assay kits. MetS was diagnosed based on the International Diabetes Federation criteria. Logistic regression was used to assess the association between gastric biomarkers and MetS.
RESULTS:Among the 24 635 participants, the overall prevalence of MetS was 35.72%, with a higher rate in males than in females (42.41% vs 24.31%). Compared with the non-MetS group, MetS group were older and had higher metabolic-related diseases rate, Helicobacter pylori infection rate, body mass index (BMI), waist circumference, systolic and diastolic blood pressure, total cholesterol, triglycerides, fasting blood glucose, glycated hemoglobin, and creatinine levels (all P<0.05). Serum G-17 levels were significantly elevated in the MetS group, and PGI levels decreased (both P<0.05). Males had higher G-17, PGI, PGII, and PGI/PGII ratios than females (all P<0.05). Subgroup analysis revealed that G-17 was consistently elevated in MetS patients regardless of sex, whereas PGI was decreased. PGII levels exhibited sex-specific differences. After adjusting for confounders, Logistic regression analysis revealed that high G-17 level was independently associated with MetS, with a stronger correlation observed in males. Moreover, G-17 level progressively increased with higher MetS scores (all P<0.05).
CONCLUSIONS:Serum G-17 level is positively associated with both the presence and severity of MetS, with a more pronounced correlation in males, suggesting its potential involvement in MetS-related metabolic dysregulation.
